orkshop 3 rd Edition Innovation in HIV and Viral Hepatitis Scientific Programme

Transcription

1 3 rd Edition Con l adesione del Presidente della Repubblica Scientific Programme orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Coordinators Antonella d Arminio Monforte (Milan, I) Carlo Federico Perno (Rome, I) Massimo Puoti (Milan, I) Milan, Italy Palazzo delle Stelline January 26-27, 205

2 Depositato presso AIFA in data 08/05/4

3 orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Endorsements Ministero della Salute Istituto Superiore di Sanità Agenzia Italiana del Farmaco Regione Lombardia Università degli Studi, Milan Dipartimento di Scienze della Salute, Università degli Studi, Milan Università degli Studi Tor Vergata, Rome Azienda Ospedaliera San Paolo - Polo Universitario, Milan Azienda Ospedaliera Niguarda Ca Granda, Milan Fondazione Policlinico Tor Vergata, Rome SIMIT, Società Italiana Malattie Infettive e Tropicali SIVIM, Società Italiana di Virologia Medica AISF, Associazione Italiana per lo Studio del Fegato AMCLI, Associazione Microbiologi Clinici Italiani Fondazione AVIRALIA Fondazione ICONA ANLAIDS, Associazione Nazionale per la lotta contro l AIDS EpaC Associazione Onlus LILA, Lega Italiana per la lotta contro l AIDS Associazione NADIR NPS Italia, Network Persone Sieropositive Honorary President Mauro Moroni Professor Emeritus, University of Milan I Scientific Coordinators Antonella d Arminio Monforte San Paolo Hospital, University of Milan I Carlo Federico Perno University of Tor Vergata, Rome I Massimo Puoti Niguarda Ca Granda Hospital, Milan I Scientific Secretariat Francesca Ceccherini-Silberstein University of Tor Vergata, Rome I Giulia Marchetti San Paolo Hospital, University of Milan I Roberto Rossotti Niguarda Ca Granda Hospital, Milan I

4

5 Faculty Alessio Michele Aghemo Foundation IRCCS Maggiore Hospital, University of Milan I Adriana Ammassari IRCCS - INMI Lazzaro Spallanzani, Rome I Massimo Andreoni University of Tor Vergata, Rome I Gioacchino Angarano University Hospital of Bari I Mario Angelico University of Tor Vergata, Rome I Andrea Antinori IRCCS - INMI Lazzaro Spallanzani, Rome I Guido Antonelli University Hospital Umberto I and Sapienza University, Rome I Stefano Bonora University of Turin I Raffaele Bruno University of Pavia I Savino Bruno Fatebenefratelli Hospital, University Milan Bicocca, Milan I Andrea Calcagno University of Turin I Giampiero Carosi Professor Emeritus, University of Brescia I Antonella Castagna San Raffaele Scientific Institute, Milan I Dario Cattaneo Luigi Sacco Hospital, University of Milan I Francesca Ceccherini-Silberstein University of Tor Vergata, Rome I Antonella Cingolani Catholic University, Rome I Massimo Clementi University Vita-Salute San Raffaele, Milan I Massimo Colombo Foundation IRCCS Maggiore Hospital, University of Milan I Andrea Cossarizza University Hospital of Modena and Reggio Emilia, Modena I Antonella d Arminio Monforte San Paolo Hospital, University of Milan I Gabriella d Ettorre University Hospital Umberto I, Rome I Andrea De Luca Siena University Hospital, Siena I Andrea De Maria University of Genoa, IRCCS AOU San Martino - IST Genoa I Giovanni Di Perri University of Turin I Daniel C. Douek Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda USA Carlo Ferrari University Hospital of Parma I Courtney V. Fletcher University of Nebraska Medical Center, College of Pharmacy, Omaha USA Charles W. Flexner Johns Hopkins University, Baltimore USA Giovanni Battista Gaeta Second University of Naples I Massimo Galli Luigi Sacco Hospital, University of Milan I Alessia Maria Giorgini San Paolo Hospital, University of Milan I Enrico Girardi IRCCS - INMI Lazzaro Spallanzani, Rome I Andrea Gori San Gerardo Hospital, Monza I Peter Hunt University of California, San Francisco USA Paul Klenerman Nuffield Department of Medicine, University of Oxford UK Adriano Lazzarin University Vita-Salute San Raffaele, Milan I Massimo Levrero Sapienza University, Rome I Miriam Lichtner Sapienza University of Rome, Polo Pontino, Latina I Giulia Marchetti San Paolo Hospital, University of Milan I Fabio Marra University of Florence I Claudio Maria Mastroianni Sapienza University of Rome, Polo Pontino, Latina I Gabriele Missale University Hospital of Parma I Mauro Moroni Professor Emeritus, University of Milan I Cristina Mussini University Hospital of Modena and Reggio Emilia, Modena I Carlo Federico Perno University of Tor Vergata, Rome I Massimo Pinzani Institute for Liver and Digestive Health, University College London, Royal Free Hospital, London UK Teresa Maria Pollicino G. Martino University Hospital, Messina I Massimo Puoti Niguarda Ca Granda Hospital, Milan I Giovanni Raimondo University Hospital of Messina I Giuliano Rizzardini Luigi Sacco Hospital, University of Milan I Stefano Rusconi Luigi Sacco Hospital, University of Milan I Teresa Antonia Santantonio University Hospital of Foggia I Annalisa Saracino University Hospital of Bari I Guido Silvestri Emory University School of Medicine, Yerkes National Primate Research Center, Atlanta USA Mario Strazzabosco University Milan Bicocca, Milan I Valentina Svicher University of Tor Vergata, Rome I Gloria Taliani Sapienza University, Rome I Camilla Tincati San Paolo Hospital, University of Milan I Erica Villa University of Modena and Reggio Emilia, Modena I Massimo Zuin San Paolo Hospital, University of Milan I 5

6 orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Programme January 26, Welcome addresses M. Moroni Rationale and presentation of the Workshop A. d Arminio Monforte, C.F. Perno, M. Puoti OPENING LECTURES Conveners: G. Antonelli, A. De Maria Mechanisms of protection from SIV/HIV disease progression G. Silvestri Impact of HIV & HCV viral burden at population level: what strategies to contain epidemics? E. Girardi Discussion M. Clementi, G.B. Gaeta, A. Lazzarin SESSION Mechanisms of viral persistence: what role for the virus and what for the host? Conveners: G. Di Perri, M. Strazzabosco HIV - What obstacles for the cure? The host vs the virus D.C. Douek HCV - Why the virus becomes chronic? P. Klenerman HBV - Why the virus becomes chronic? T.M. Pollicino Discussion A.M. Aghemo, A. Cossarizza Lunch and poster discussion SESSION 2 Oral communications based on selected abstracts Conveners: S. Bruno, C.M. Mastroianni PNPLA3 variant is an independent predictor of severe steatosis in patients with chronic hepatitis C and HIV infection C. Sagnelli, M. Merli 2, C. Uberti-Foppa 2, N. Coppola 3, H. Hasson 2,, G. Cirillo 4, A. Gradone 4, S. Salpietro 2, C. Minichini 3, E. Miraglia Del Giudice 4, A. Lazzarin 2, E. Sagnelli 3 Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy; 2 Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; 3 Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy; 4 Department of Pediatrics, Second University of Naples, Naples, Italy HIV- Impairs CD62L Expression and Function L. Vassena, E. Giuliani, M. Doria Bambino Gesù Children's Hospital, IRCCS, Rome, Italy Clonal Expansion of Infected Cells as a Mechanism of HIV Persistence F. Simonetti,2, S. Hill 2, M. Gouzoulis 2, W. Shao 3, X. Wu 3, M. Kearney 3, S. Hughes 3, J. Coffin 3, J. Mellors 4, F. Maldarelli 2 University of Milan, Milan, Italy; 2 National Cancer Institute, Frederick, MD, USA; 3 Leidos Biomedical Research, Frederick, MD, USA; 4 Tufts University, Boston, MA, USA; 5 University of Pittsburg, PA, USA 6

7 January 26, 205 HCV NS3 Quasispecies in Liver and Plasma and Dynamics of Telaprevir-resistant Variants Assessed by UDPS in Breakthrough Patients: a Case Study B. Bartolini, M. Selleri, A.R. Garbuglia, E. Giombini, G. D Offizi, M.R. Capobianchi National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy Immune cytotoxic response selects a growing number of defective viral variants during the natural history of HBV infection, some of which are not detectable in the periphery: possible implications for the pathogenesis and for the clinical management of patients with chronic hepatitis B C. Minosse, M. Selleri, A. Baiocchini 2, E. Giombini, S. Coen, P. Zaccaro, G. Rozera, D. Vincenti, U. Visco Comandini 3, R. Lionetti 3, M. Montalbano 3, G. D'Offizi 3, M.R. Capobianchi, S. Menzo 4 Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 2 Laboratoy of Pathology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 3 st Clinical Division, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 4 Laboratory of Virology, Università Politecnica delle Marche, Ancona, Italy A potential role of dendritic cell and monocytes assessment in predicting response to therapy in HCV infected subjects S. Vita, M. Lichtner 2, S. Savinelli, C. Mascia, T. Tieghi 2, R. Marocco 2, P. Zuccalà, F. Schiavone, F. Mengoni, V. Vullo, C.M. Mastroianni 2 Public Health and Infectious Diseases, Sapienza University, Rome, Italy; 2 Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy SESSION 3 Beyond viral undetectability in plasma: which markers of therapy outcome Conveners: M. Colombo, G. Rizzardini HIV - Case presentation and open questions HIV case presentation G. d Ettorre Open questions P. Hunt HCV - Case presentation and open questions HCV case presentation F. Ceccherini-Silberstein Open questions M. Zuin HBV - Case presentation and open questions HBV case presentation V. Svicher Open questions G. Raimondo Discussion A. Gori, C. Mussini Coffee break SESSION 4 Eradication and functional cure: pharmacology Conveners: A. Antinori, G. Carosi Framing the problem A. Antinori Insight the HIV reservoirs C.V. Fletcher Insight the HCV-related cirrhosis F. Marra Long-Acting injectable ARVs: dream or reality? C.W. Flexner Insight the HBV reservoirs M. Levrero Discussion A. Calcagno, D. Cattaneo 7

8 orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Scientific Programme January 27, LECTURE Conveners: G. Angarano, M. Galli CCR5 and modulation of fibrosis progression in HIV/HCV coinfection R. Bruno Discussion SESSION 5 Difficult to treat patients: what therapeutic strategy? Conveners: M. Andreoni, M. Angelico Framing the problem M. Andreoni High HIV viremia: case presentation and open questions Does more aggressive anti HIV therapy work? C. Tincati Open questions A. De Luca HCV-related cirrhosis: case presentation and open questions What treatment options for low HCV decay? A.M. Giorgini Open questions M. Pinzani Discussion G. Missale, S. Rusconi Coffee break SESSION 6 Oral communications based on selected abstracts Conveners: C. Ferrari, A. Saracino Inherent transcriptional signatures of NK cells are associated with response to IFNα + ribavirin therapy in patients with Hepatitis C Virus M.L. Ascierto,2, F. Bozzano,3, D. Bedognetti 4, F. Marras 5, C. Schechterly 6, A. Picciotto 7, S. Marenco 7, Y. Zhao 8, V. De Giorgi 6, M. Sommariva 6, L. Moretta 5, E. Wang 4, H.J. Alter 6, F.M. Marincola 4, A. De Maria,3,7 Department of Health Sciences, University of Genoa, Italy; 2 Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; 3 Department of Experimental Medicine, University of Genoa, Italy; 4 Sidra Medical and Research Centre, Doha, Qatar; 5 Istituto Giannina Gaslini, Genova, Italy; 6 Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA; 7 IRCCS Az. Osp. Univ. San Martino-IST Istituto Nazionale Ricerca sul Cancro, Genova, Italy; 8 Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Sofosbuvir-based all-oral treatment for elderly Chronic Hepatitis C patients: a costeffectiveness analysis A. Ciaccio, P.A. Cortesi 2, G. Bellelli 3, M. Rota 4, M. Rota, S. Okolicsanyi, L.G. Mantovani 2, G. Annoni 3, M. Strazzabosco,5 Department of Surgery and Translational Medicine; 2 Research Centre on Public Health (CESP); 3 Department of Health Sciences, Geriatric Medicine; 4 Department of Health Sciences, Centre of Biostatistics for Clinical Epidemiology, University of Milan-Bicocca, Milan, Italy; 5 Liver Center & Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA 8

9 January 27, 205 Peripheral and CSF immune-activation and inflammation are associated with elevated CSF HIV RNA in antiretroviral naïve HIV-infected individuals E. Merlini, F. Bai, F. Iannuzzi, M. Trunfio, A. Calcagno 2, S. Bonora 2, E.S. Cannizzo, M. Basilissi, G. Marchetti and A. d Arminio Monforte University of Milan, Dept of Health Sciences, Italy; 2 University of Turin, Italy Final results of Telaprevir-based therapy in HCV/HIV patients with severe fibrosis A. Gori, M. Doroana 2, O. Chernova 3, J. Rockstroh 4, D. Banhegyi 5, C. Bergin 6, G. Verucchi 7, R. DeMasi 8, B. Hadacek 9, M. Nelson 0 Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy; 2 Servico de Doencas Infecciosas, Hospital de Santa Maria, Lisbon, Portugal; 3 State Healthcare Institution, Tolyatti, Russian Federation; 4 Department of Internal Medicine, University Hospital Bonn, Bonn, Germany; 5 Szent Laszlo Hospital, Budapest, Hungary; 6 Department of Genitourinary Medicine and Infectious Diseases, St James Hospital, Dublin, Ireland; 7 Division of Infectious Diseases, University of Bologna, Bologna, Italy; 8 Janssen Research and Development LLC, Titusville, NJ, USA; 9 Janssen Pharmaceuticals, Paris, France; 0 Chelsea and Westminster Hospital, London, United Kingdom Slow HCV kinetics following Sofosbuvir + Ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C V. Cento, M.F. Donato 2, I. Lenci 3, M. Rendina 4, V.C. Di Maio, M. Milana 3, S. Monico 2, M. Aragri, R. Alfieri 5, A. Abedrabbo 3, D. Sforza 6, M. Manuelli 6, L. Mameli 7, M.C. Sorbo, R. Canu 8, M.L. Ponti 8, C. Chialà 4, F. Malinverno 2, S. Marenco 9, L. Milanesi 5, A. Picciotto 9, G. Rossi 2, A. Di Leo 4, G. Tisone 6, F. Zamboni 7, R. Ganga 8, M. Colombo 2, C.F. Perno,0, M. Angelico 3, F. Ceccherini-Silberstein Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy; 2 Gastroenterology and Liver Transplant Units, Fondazione IRCCS Cà Granda Maggiore Hospital Policlinico and University of Milan, Milan, Italy; 3 Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy; 4 Gastroenterology and Digestive Endoscopy, University Hospital, Policlinico Bari, Bari, Italy; 5 Institute for Biomedical Technologies, National Research Council, Segrate (MI), Italy; 6 Liver Transplant Centre, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy; 7 Liver Transplant Centre, Azienda Ospedaliera G Brotzu, Cagliari, Italy; 8 Internal Medicine Unit, Azienda Ospedaliera G Brotzu, Cagliari, Italy; 9 Unit of Diagnosis and Therapy of Liver Diseases, San Martino Hospital, Genoa, Italy; 0 Virology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy SESSION 7 Infection and gender: any differences? Conveners: A. Cingolani, T.A. Santantonio Framing the problem A. Ammassari Antiviral drug toxicity and pharmacokinetics S. Bonora HIV: which biological differences according to gender? G. Marchetti HCV: natural history of chronic liver disease E. Villa The setting of HIV/HCV coinfection G. Taliani Discussion A. Castagna, M. Lichtner SESSION 8 Closing remarks Conveners: A. d Arminio Monforte, C.F. Perno, M. Puoti 9

10

11 Selected Posters. Experience of acute hepatitis C and HIV co-infection A. Iodice, V. Iodice Azienda Ospedaliera Caserta, Italy 2. Differential Maturing Level of NK Cells Derived from HIV+ Patient Peripheral Blood CD34+ Cells Compared with to NK Maturing from Cord Blood Precursors F. Bozzano,2, F. Marras 3, G. Cenderello 4, C. Dentone 5, A. Di Biagio 6, L.A. Nicolini 6, C. Viscoli 7, G. Bentivoglio 3, F. Antonini 3, C. Cantoni 3, M.L. Ascierto 8,9, A. Moretta,2, L. Moretta 3, A. De Maria 2,6 Department of Experimental Medicine, University of Genoa, Italy; 2 Center of Excellence for Biomedical Research, University of Genoa, Italy; 3 G. Gaslini Institute, Genoa, Italy; 4 Department of Infectious Diseases, Ospedali Galliera, Genoa, Italy; 5 San Remo Hospital, Imperia, Italy; 6 IRCCS AOU San Martino-IST Genoa, Italy; 7 Clinical Infectious Diseases, IRCCS AOU San Martino- IST Genoa, Italy; 8 Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA; 9 Department of Oncology, Johns Hopkins University, Baltimore, MD, USA 3. Distinct NK Cell Regulation in Virologically Discordant Non Progressor Patients, Addictional to EC/LTNP F. Marras, F. Bozzano 2, A. Di Biagio 3, L. Nicolini 3, C. Viscoli 3, C. Dentone 4, E. Pontali 5, S. Boni 6, M. Setti 3,7, G. Orofino 8, E. Mantia 9, L. Moretta, C. Orlandi 0, A. Casabianca 0, M. Magnani 0, A. De Maria 2, Istituto Giannina Gaslini, Genoa, Italy; 2 Department of Experimental Medicine, DIMES, University of Genoa, Genoa, Italy; 3 Department of International Medicine and Infectious Disease IRCCS A.O.U. SanMartino-IST Genoa, Italy; 4 Unità di Malattie Infettive, Ospedale Sanremo, Sanremo (GE), Italy; 5 Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy; 6 Unità di Malattie Infettive, Ospedale Sant Andrea, La Spezia, Italy; 7 Department of Internal Medicine, University of Genoa, Genoa, Italy; 8 Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy; 9 Unità di Malattie Infettive, Az. Osp. Santi A.B.C. Arrigo, Alessandria, Italy; 0 Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy; Center of Excellence in Biomedical Research, University of Genoa, Genoa, Italy 4. Proviral DNA and Inflammation during cart in Primary or Chronic Infection: ALPHA Study G. Rozera, I. Abbate, C. Pinnetti, N. Orchi, P. Pierro, P. Lorenzini, A. Amendola, V. Bordoni, A. Antinori, M.R. Capobianchi, A. Ammassari National Institute for Infectious Disease L. Spallanzani, Rome, Italy 5. High levels of HBsAg with low plasmatic HBV-DNA in young African refugees with HBV genotype infection: an indication for early treatment V. Malagnino, C. Sarrecchia, C. Cerva, V. Svicher 2, M. Pollicita 2, L. Colagrossi 2, M. Aragri 2, R. Salpini 2, A. Ricciardi, G. MaffongelliI, L. Dori, C.F. Perno 2, M. Andreoni, L. Sarmati Clinic of Infectious Diseases, Policlinico Tor Vergata of Rome, Italy; 2 Department of Experimental Medicine and Surgery, University of Tor Vergata, Rome, Italy 6. Bone and Vascular Diseases in HIV Infected Patients: Is There a Link? A. D Abramo, M.A. Zingaropoli, A. Oliva, C. D Agostino, M. Iannetta, G. d Ettorre, M.R. Ciardi, C.M. Mastroianni, V. Vullo Sapienza University of Rome, Italy 7. Impact of HCV RNA on Epidemiological, Viroimmunological, Clinical and Therapeutic Basal Features in HIV/HCV Positive Subjects Enrolled in Master Cohort M. Giralda, P. Nasta, F. Borghi, A. Saracino 2, F. Maggiolo 3, S. Digiambenedetto 4, M. Di Pietro 5, L. Sighinolfi 6, A. Zoncada 7, S. Costarelli 8, F. Castelli, G. Carosi 9 and the MaSTER study group University Division of Infectious and Tropical Diseases, University of Brescia, Italy; 2 Infectious Diseases, Policlinico di Bari, Italy; 3 Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 4 Infectious Diseases, Policlinico A. Gemelli - Catholic University, Roma, Italy; 5 Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy; 6 Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy; 7 Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 8 Infectious Diseases, San Gerardo Hospital, Monza, Italy; 9 MISI Foundation, Italy

12

13 Selected Posters 8. Inflammatory myeloid subsets expansion in AIDS and non AIDS presenters S. Savinelli, M. Lichtner 2, C. Mascia, R. Rossi, R. Marocco 2, E.N. Cavallari, G. d Ettorre, F. Schiavone 2, C.M. Mastroianni 2, V. Vullo Department of Public Health and Infectious Diseases, University of Rome "Sapienza, Italy; 2 Infectious Diseases Unit, Polo Pontino, University of Rome "Sapienza", Italy 9. Analysis of innate immune response in HCV mono-infected, HCV/HIV co-infected and HIV monoinfected patients under effective ART F. Schiavone 2, M. Lichtner, C. Mascia 2, S. Savinelli 2, T. Tieghi, R. Marocco, S. Vita 2, P. Zuccalà 2, R. Rossi 2, F. Mengoni 2, C.M. Mastroianni, V. Vullo 2 Infectious Diseases Unit, Sapienza University, Latina, Italy; 2 Public Health and Infectious Diseases, Sapienza University, Rome, Italy 0. A Web Portal for Clinical and Genotype Data Management for the Study of Hepatocellular Carcinoma R. Alfieri, M. Santoro 2, M. Gnocchi, M. Moscatelli, O. Carpina 3, C. Vischi 3, C. Pisano 4, V. De Murtas 4, E. Polilli 5, F. P. Antonucci 2, I. Maida 4, P. Tarquini 6, G. Garrucciu 7, F. Bandiera 8, D. Di Giammartino 6, D. Laccabue 9, A. Olivani 9, V. Borghi 0, T. Quirino, I. Lenci 2, G. Tisone 2, M. Angelico 2, C. Mussini 0, G. Rizzardini 3, M. Temponi 3, G. Parruti 5, M.S. Mura 4, F. Ceccherini-Silberstein 2, C.F. Perno 2, L. Milanesi Istituto di Tecnologie Biomediche - CNR, Segrate (MI), Italy; 2 Università degli Studi di Roma Tor Vergata, Roma, Italy; 3 Flaconix, Capriano Del Colle (BS), Italy; 4 Università degli Studi di Sassari, Sassari, Italy; 5 ASL Pescara PO Santo Spirito, Pescara, Italy; 6 Ospedale G. Mazzini di Teramo, Italy; 7 Azienda Ospedaliera Universitaria di Sassari, Italy; 8 Ospedale Santissima Annunziata di Sassari, Italy; 9 Azienda Ospedaliera-Universitaria di Parma, Italy; 0 Azienda Ospedaliero Universitaria di Modena Policlinico, Italy; Azienda Ospedaliera Ospedale di Busto Arsizio (VA), Italy; 2 Fondazione Policlinico Tor Vergata, Roma, Italy; 3 Azienda Ospedaliera e Polo Universitario Ospedale Luigi Sacco, Milano, Italy. Evaluation of Durability of 3 First-Line cart Regimens including Atazanavir/ritonavir, Darunavir/ritonavir and Raltegravir in Patients Enrolled in a Large Italian Cohort (MASTER) C. Torti,3, A. Saracino 2, C. Pezzoli 3, C. Casari 3, F. Maggiolo 4, S. Digiambenedetto 5, M. Di Pietro 6, L. Sighinolfi 7, A. Zoncada 8, S. Costarelli 9, N. Mazzini, M.C. Postorino, M. Braggion 0, G. Carosi and the MaSTER study group Unit Operation Infectious Diseases, University of Magna Grecia, Catanzaro, Italy; 2 Infectious Diseases, Policlinico di Bari, Italy; 3 Infectious Diseases, University of Brescia, Italy; 4 Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 5 Infectious Diseases, Policlinico A. Gemelli - Catholic University, Rome, Italy; 6 Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy; 7 Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy; 8 Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 9 Infectious Diseases, San Gerardo Hospital, Monza, Italy; 0 Foundation of Ca' Foscari University, Venice, Italy; MISI Foundation, Italy 3

14

15 General information Workshop Venue Palazzo delle Stelline Corso Magenta, Milan, Italy orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies CME Provider and Organizing Secretariat Milan, Italy January 26-27, 205 Effetti srl Via Gallarate, Milan, Italy Phone Fax Mail: innovation205@effetti.it orkshop Innovation in HIV and Viral Hepatitis Beyond viral undetectability: new frontiers and strategies Official language English. No simultaneous translation provided. CME accreditation The Workshop has obtained 9 CME credits (ID number 50-23) from Italian Health Ministry for the following professionals: Medical Doctor, Biologist, Territory and Hospital Pharmacist, Nurse, Medical Laboratory Technician and Psychologist. Medical specialties include: Infectious and Tropical Diseases, Hygiene, Epidemiology and Public Health, Microbiology and Virology, Allergology and Clinical Immunology, Internal Medicine and Gastroenterology. Credits will be given only to participants attending 00% of the teaching event and answering correctly to at least 75% of the final assessment questionnaire. Participants are also required to wear the identification badge during working sessions, to provide their signature for attendance tracking purposes and to complete the satisfaction questionnaire. Poster session Authors may post up their posters subject to registration. The selected posters should be affixed in the foyer outside Sala Volta (st floor), one hour before the beginning of the Workshop and taken away at the end of the scientific works. Posters should be prepared in English. During poster discussion, authors are kindly requested to remain close to their own poster for answering questions. Cyber point A Cyber point is available at exhibition area in the foyer outside Sala Volta (st floor). Slide center A slide center will be available to speakers, with computers, CD writer, printer and technical support. Only Powerpoint slide presentations will be accepted. If a special equipment is needed, it should be communicated in advance to the Organizing Secretariat. Slides must be submitted 2 hours before the scheduled presentation. Technical equipment Congress room is suitable for Powerpoint presentations and equipped with computers and overhead projectors. Speakers may not use their own computers for their presentations. Exhibition area A technical-pharmaceutical and scientific publishing exhibition area will be open from :00 a.m. on Monday January 26 th to 0:30 p.m. on Tuesday January 27 th. Web repository Abstracts (oral and poster) and slide presentations of authors who provide their consent will be published on Workshop web site ( at the end of the event.

16 The Scientific Coordinators, the Scientific Secretariat and the CME Provider wish to thank for support given in the form of unrestricted educational grants the following Companies: PLATINUM SPONSOR GOLD SPONSOR OTHER SPONSORS Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd has had no input into the content of the materials and presentations.